In this interview, David Flores sits down with Dr. Mike Raymont, Director/CEO of Albert Labs, a laboratory based clinical research and drug development enterprise focused on improving patient access to psychedelic assisted therapies through accelerated regulatory approval pathways with a current focus on psilocybin to treat anxiety in cancer patients.
Albert Labs is the first psychedelic company to use a different pathway to regulatory approval, pioneered primarily in the UK, utilizing real world evidence studies to accelerate access to psychedelic therapy for narrow indications of urgent and unmet needs. This speed to market strategy is what leads Dr. Raymont to believe that Albert Labs will be “the first to market with a regulated drug by the end of 2022 and reach profitability by 2023-2024”.
To learn more about Albert Labs, visit: albertlabs.com
#Albert Labs #Psychedelics #Anxiety
source
